Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Karlsson C, Hansson L, Celsing F, Lundin J . Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007; 21: 511–514.

    Article  CAS  Google Scholar 

  2. Laurenti L, Piccioni P, Tarnani M, Efremov DG, Fiorini A, Garzia M et al. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukaemia. A single center experience. Haematologica 2005; 90: 1143–1145.

    CAS  PubMed  Google Scholar 

  3. Cheson BD, Bennet JM, Greper M, Kay M, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  4. Laurenti L, Piccioni P, Tarnani M, Chiusolo P, Piccirillo N, Rumi C et al. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 153–154.

    Article  CAS  Google Scholar 

  5. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786–2792.

    CAS  PubMed  Google Scholar 

  6. Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al., GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006; 91: 1689–1692.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Ematologia, Policlinico A Gemelli, Universita' Cattolica del Sacro Cuore, Roma, Italy

    L Laurenti, M Tarnani, P Chiusolo, L De Padua, S Sica & G Leone

  2. ICGEB Outstation CNR Monterotondo-Roma, Roma, Italy

    D G Efremov

Authors
  1. L Laurenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Tarnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D G Efremov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Chiusolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L De Padua
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Leone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Laurenti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laurenti, L., Tarnani, M., Efremov, D. et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 21, 1819–1821 (2007). https://doi.org/10.1038/sj.leu.2404703

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404703

  • Springer Nature Limited

This article is cited by

Search

Navigation